Emerging infectious diseases · 2011
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.
СтатьяМногоцентровое исследованиеПоддержка правительства СШАПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Benjamin J, Pappas Peter G, Wannemuehler Kathleen A, Alexander Barbara D, Anaissie Elias J, Andes David R, Baddley John W, Brown Janice M, Brumble Lisa M, Freifeld Alison G, Hadley Susan, Herwaldt Loreen, Ito James I, Kauffman Carol A, Lyon G Marshall, Marr Kieren A, Morrison Vicki A, Papanicolaou Genovefa, Patterson Thomas F, Perl Trish M, Schuster Mindy G, Walker Randall, Wingard John R, Walsh Thomas J, Kontoyiannis Dimitrios P
Аннотация
Recent reports describe increasing incidence of non-Aspergillus mold infections in hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients. To investigate the epidemiology of infections with Mucorales, Fusarium spp., and Scedosporium spp. molds, we analyzed data from the Transplant-Associated Infection Surveillance Network, 23 transplant centers that conducted prospective surveillance for invasive fungal infections during 2001-2006. We identified 169 infections (105 Mucorales, 37 Fusarium spp., and 27 Scedosporium spp.) in 169 patients; 124 (73.4%) were in HCT recipients, and 45 (26.6%) were in SOT recipients. The crude 90-day mortality rate was 56.6%. The 12-month mucormycosis cumulative incidence was 0.29% for HCT and 0.07% for SOT. Mucormycosis incidence among HCT recipients varied widely, from 0.08% to 0.69%, with higher incidence in cohorts receiving transplants during 2003 and 2004. Non-Aspergillus mold infections continue to be associated with high mortality rates. The incidence of mucormycosis in HCT recipients increased substantially during the surveillance period.